Información:
Error:
ID
14501
Descripción
Orthomolecular Therapy and Asthma in Children; ODM derived from: https://clinicaltrials.gov/show/NCT00672529
Link
https://clinicaltrials.gov/show/NCT00672529
Palabras clave
Versiones (1)
- 19/4/16 19/4/16 -
Titular de derechos de autor
CC BY-NC 3.0
Subido en
19 de abril de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Asthma NCT00672529
Eligibility Asthma NCT00672529
- StudyEvent: Eligibility
Similar models
Eligibility Asthma NCT00672529
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
age
Item
male or female aged 7 to 18 years
boolean
C0001779 (UMLS CUI [1])
mild to moderate asthma
Item
mild to moderate asthma diagnosed by a respirologist
boolean
C1960046 (UMLS CUI [1])
C1960047 (UMLS CUI [2])
C1960047 (UMLS CUI [2])
budesonide
Item
use of budesonide at a dose of 200-800 µg/d (or equivalent corticosteroid therapy) for ≥3 months
boolean
C0054201 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
stable asthma
Item
stable asthma, defined as no significant change in the regular asthma medication and no acute asthma exacerbation requiring corticosteroid rescue for at least 3 months before enrollment in the run-in phase. asthma symptoms must be under good control
boolean
C0004096 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0349790 (UMLS CUI [2])
C0205360 (UMLS CUI [1,2])
C0349790 (UMLS CUI [2])
fev1
Item
baseline forced expiratory volume at 1 second (fev-1) >= 70% of the predicted normal value.
boolean
C0748133 (UMLS CUI [1])
orthomolecular therapy
Item
possible participants treated with orthomolecular therapies within the previous year will require a wash out period of 7 days prior to enrolment in the trial. (vitamin c > 200mg, vitamin e >50iu, vitamin b12 > 100µg, magnesium > 200mg, selenium > 50µg, omega-3 > 300mg, quercetin > 3mg, vitamin b6 > 75mg will all be considered orthomolecular doses).
boolean
C0029340 (UMLS CUI [1])
hypersensitivity to any component of the orthomolecular therapy or placebo
Item
known hypersensitivity to any component of the orthomolecular therapy or placebo.
boolean
C0020517 (UMLS CUI [1,1])
C0029340 (UMLS CUI [1,2])
C0032042 (UMLS CUI [1,3])
C0029340 (UMLS CUI [1,2])
C0032042 (UMLS CUI [1,3])
comorbidity
Item
acute infectious sinusitis or respiratory tract infection or active lung disease other than allergic asthma within 1 month or any other significant systemic disease within 3 months of the study entry visit.
boolean
C0009488 (UMLS CUI [1])